logically similar appearances seen in polyarteritis nodosa, Goodpasture's syndrome, Henoch-Schonlein syndrome, and idiopathic focal nephritis associated with mesangial IgA/IgG deposits (Berger, 1969; Berger et al., 1971) . Serial determinations of serum complement were valuable in assessing activity of the immune-complex disease and its response to therapy, and in one of our patients the fall in plasma C3 concentration was helpful in diagnosing relapse.
Even before the advent of antibiotics renal failure in subacute infective endocarditis was unusual (Baehr, 1921) . It was, however, a striking feature in this group of patients, four of whom needed peritoneal dialysis. Two of these patients recovered good renal function, one died of cardiac failure shortly after admission, and the fourth patient, with extensive glomerular destruction, had irreversible renal failure. In one of the patients who recovered there was also clinical and histological evidence of acute tubular necrosis but in the remaining patients renal failure was due solely to glomerulonephritis. The striking improvement in renal function after eradication of infection emphasizes the importance of persistence of antigen in the progression of nephritis and the degree of recovery that is possible unless widespread glomerular scarring has already occurred. The importance of early diagnosis and effective treatment is evident. McIntosh, R. M., et al., (1971 were the first to suggest that beta-adrenoceptor blockade might be effective in the treatment of pathological anxiety. Some more recent reports support this view (Wheatley, 1969; Conway, 1971; Bonn et al., 1972; McMillin, 1973 (Hamilton, 1959) in which 100-mm linear scales were used instead of categorical ones (Lader and Marks, 1971 . The absence of such a non-specific response in our patients can be explained by the chronicity of their complaints.
The means of the numbers of capsules taken daily were placebo, 3 1; diazepam, 4-8 (9-6 mg); propranolol, 3 0 (120 mg).
FOLLOW-UP
The patients were followed-up for a least six months after completing the trial. At six months two patients were still taking propranolol in small doses, five were taking diazepam (or chlordiazepoxide), and two were taking both. The nature of their symptoms did not alter appreciably. Kendall's coefficient of concordance (w) (Siegel, 1956 ) = 0-51; P<O0O1.
Statistical testing of the Hamilton ratings was carried out by a split-plot analysis of variance. Significant F ratios for drug and drug times group interaction were subjected to Tukey's test (Winer, 1962) to find the critical difference between individual drug means. The mean Hamilton rating of anxiety was significantly lower in both'groups for diazepam (F = 10-2; D.F. 2, 16; P < 001) compared with the other
Discussion
The results indicate that diazepam is generally more effective fthan propranolol (and placebo) in the treatment of morbid anxiety. Though the patients were a highly-selected sample whose anxiety was more persistent than usual there is no reason to believe that it was qualitatively different from milder forms. Nevertheless, propranolol does have important clinical effects in somatically anxious patients. Its efficacy in this group is comparable to diazepam and its use is preferable because it rarely produces sedation, is very safe, and not prone to abuse. It must be emphasized that the patients who responded relatively well to propranolol did not necessarily have more somatic symptoms than t-hose in the psychic anxiety group, bu-t they complained of ,them primarily and tended to deny the psychological aspects of their condition.
Since somatic symptoms become more severe as anxiety imcreases it was important to ensure that the difference between the groups was not based on -the severity of -the conditions. A one-way analysis of variance on the patients' scores before treatment showed no significant difference between the two groups, so this possibility was unlikely.
It is interesting that most patients with psychic anxiety preferred placebo to propranolol. Lader and Tyrer (1972) found that propranolol in a single dose of 120 mg caused normal people to feel significantly more troubled than when on placebo and that these feelings occurred in ithe absence of sedation. Perhaps alteration of bodily sensations may be perceived as unpleasan-t by those who do not complain of somatic anxiety. The therapeutic indications for propranolol in pathological anxiety seem to be confined to patients who do not complain of anxiety even though -their somatic symptoms are clearly due to anxiety. Symptoms caused by tachycardia and tremor, both of which are significantly lessened by betaadrenoceptor blockade in anxious patient-s (Turner et al., 1965; Tyrer and Lader, 1973) , are especially likely to be helped. In such patients the removal of the symptom is enough to bring considerable clinical relief. This supports the view that bodily symptoms may be more fundamental in morbid emotion than is usually thought (Tyrer, 1973) , and is consistent with the long-standing clinical impression that patients wit,h somatic complaints are best treated -by somatic therapy (Misch, 1935) .
The results of our study are also consistent wi-th previous reports of the effectiveness of beta-receptor blockade in other conditions. It could be argued that the primary complain-t in "hyperdynamic beta-adrenergic circulatory state" (Frohlich et al., 1966) , "nervous heart complaint" (Nordenfelt et al., 1968) , "hyperventilation syndrome" (Suzman, 1968) , and "vasoregulatory asthenia" (Holmgren et al., 1957) is that of anxiety presenting in the guise of somatic malifunotion. In all these conditions beta-receptor blockade is beneficial (Marsden, 1971) . If the speotrum of somatic anxiety is extended to include such functional disorders the type of patient suitable for treatment with beta-blocking agents is better defined. It remains to be seen whether there are differences in response between individual beta-blocking agents but from our knowledge of their clinical effects in other conditions this seems unlikely, provided they are given in equipotent dosage (Thadani et al., 1973) . The clinical presentation of anxiety is so varied and the pharmacological differences between the beta-blocking drugs so small by comparison that it is the selection of the right patient for itreatment rather than choice of drug which is likely to be critical for success.
